Abbvie Inc (ABBV)

[DewDiligence]

ABBV takes option to acquire aesthetic-device company:

https://finance.yahoo.com/news/allergan-aesthetics-enters-option-acquire-210500724.html

Financial terms were not disclosed.

[Taurus69]

$abbv $107.15 ^ 1.88 (1.79%)
Volume: 6,148,110 @12/31/20 7:58:35 PM EST

[Taurus69]

$abbv $103.39 ^ 0.11 (0.11%)
Volume: 1,378,650 @12/24/20 5:00:00 PM EST

[Taurus69]

$abbv $104.99 ^ 0.95 (0.91%)
Volume: 5,490,541 @12/02/20 6:23:29 PM EST

[Taurus69]

$abbv $104.97 ^ 0.77 (0.74%)
Volume: 4,418,751 @11/27/20 5:00:00 PM EST

[whytestocks]

JUST IN: $ABBV Like Dividends? I Bet You'll Love These 3 Stocks

Investment fads come and go, and growth stories eventually end. Income-producing stocks always fit into a portfolio, however, even if those dividends are being collected to purchase other sorts of positions. And, given the uncertainty that lies in our immediate future, a little more certain...

In case you are interested ABBV - Like Dividends? I Bet You'll Love These 3 Stocks

[Taurus69]

$abbv $99.0 ^ 1.4 (1.43%)
Volume: 6,877,285 @11/13/20 4:41:03 PM EST

[Taurus69]

$abbv $85.11 ^ 4.44 (5.50%)
Volume: 18,095,186 @10/30/20 7:58:30 PM EDT

[whytestocks]

Just In: $ABBV 5 No-Brainer Stocks to Buy if Donald Trump Wins in November

Talking heads get paid to speculate about what the market will do in different scenarios, but it is rare that anyone can truly know how a particular company, industry, or the overall market will fare based on a presidential election. That said, a reelection of a U.S. President offers mo...

Got this from ABBV - 5 No-Brainer Stocks to Buy if Donald Trump Wins in November

[whytestocks]

Just In: $ABBV AbbVie (ABBV) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q3 2020 Earnings Call Oct 30, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: AbbVie (ABBV) Q3 2020 Earnings Call Transcript

In case you are interested ABBV - AbbVie (ABBV) Q3 2020 Earnings Call Transcript

[whytestocks]

News; $ABBV How AbbVie Beat Expectations in Q3

AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited about so far in 2020. As of Thursday's close, its shares were down by 9% year to date, lagging well behind the S&P 500 index 's performance. However, the big drugmaker's shareholders now have a reaso...

In case you are interested ABBV - How AbbVie Beat Expectations in Q3

[whytestocks]

News; $ABBV AbbVie Reports Third-Quarter 2020 Financial Results

AbbVie Reports Third-Quarter 2020 Financial Results - Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83 - Delivers Third-Quarter Net Revenues of $12.902 Billion on a GAAP Basis, an Increase of 52.1 Percent on a Reported Basis; Adjusted...

Read the whole news ABBV - AbbVie Reports Third-Quarter 2020 Financial Results

[whytestocks]

Breaking News: $ABBV 2 No-Brainer Dividend Stocks Yielding More Than 4%

For dividend-seeking investors, looking at a stock's yield is important. High yields tend to be more attractive than low yields if all other things remain equal. But in real life, things are rarely equal, so before purchasing shares of a company because of its dividend, it's essential to lo...

Got this from ABBV - 2 No-Brainer Dividend Stocks Yielding More Than 4%

[GE_Jim]

AbbVie (NYSE:ABBV) declares $1.30/share quarterly dividend, 10.2% increase from prior dividend of $1.18.

Forward yield 6.45%

Payable Feb. 16; for shareholders of record Jan. 15; ex-div Jan. 14.

[DewDiligence]

ABBV 3Q20 results—2020 guidance raised slightly:

https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2020-financial-results

New 2020 non-GAAP EPS guidance is $10.47-10.49 (from prior range of $10.35-10.45).

[conix]

Back to a nice dividend yield. LOL

[DewDiligence]

ABBV phase-3 trials in presbyopia hit primary endpoint:

https://finance.yahoo.com/news/allergan-abbvie-company-announces-positive-120000680.html

Detailed data to be presented at an unspecified medical conference.

AGN-190584, a once-daily eye drop, was inherited from Allergan.

[conix]

ABBV is in a low risk buying range, IMO.

Healthy dividend. "Healthy" sector.

[Taurus69]

$abbv $83.01 v -1.24 (-1.47%)
Volume: 9,746,011 @10/21/20 7:58:03 PM EDT

[StockHighAlert-]

The Race To Treat Spinal Cord Injury is On: AbbVie pharmaceuticals $ABBV and RespireRx Pharmaceuticals Inc. (RSPI) on Watch https://dailytrendingstocks.com/the-race-to-treat-spinal-cord-injury-is-on-abbvie-pharmaceuticals-abbv-and-respirerx-pharmaceuticals-inc-rspi-on-watch/?source=push_monkey

[whytestocks]

JUST IN: $ABBV Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades

If you are in a financial position to invest $5,000 in new stocks today, you will find no shortage of exciting options. If you would like to balance the potential for solid returns with long-term stability, dividend stocks might be the best place to start your search. Companies that have a ...

Find out more ABBV - Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades

[conix]

ABBV Dividend History

https://www.nasdaq.com/market-activity/stocks/abbv/dividend-history

[Taurus69]

$abbv $88.45 ^ 0.75 (0.86%)
Volume: 7,312,995 @10/12/20 5:52:38 PM EDT

[Taurus69]

$abbv $85.89 ? 0.0 (0.00%)
Volume: 364 @10/07/20 5:13:08 AM EDT

[conix]

ABBV Chart

[Taurus69]

$abbv $90.49 ^ 0.79 (0.88%)
Volume: 5,212,480 @09/14/20 7:49:58 PM EDT

[Taurus69]

$abbv $89.74 ^ 0.09 (0.10%)
Volume: 8,385,750 @09/11/20 7:58:55 PM EDT

[DewDiligence]

ABBV, IMAB ink deal to commercialize IMAB’s anti-CD47 mAb globally (excluding Greater China):

https://finance.yahoo.com/news/abbvie-mab-enter-global-strategic-110000707.html

AbbVie and I-Mab announced today that AbbVie and I-Mab have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

… The collaboration established today provides AbbVie with an exclusive global license, excluding greater China, to develop and commercialize lemzoparlimab. Both companies will collaborate to design and conduct further global clinical trials to evaluate lemzoparlimab in multiple cancers. I-Mab retains all rights to develop and to commercialize lemzoparlimab in mainland China, Macau and Hong Kong. The collaboration also allows for potential collaboration on future CD47-related therapeutic agents. Each party will have the opportunity subject to further licenses to explore each other's related programs in their respective territories.

The companies will share manufacturing responsibilities with AbbVie being the primary manufacturer for global supply. The collaboration will accelerate I-Mab's establishment of commercial production operations in China.

…Under the terms of the agreement, AbbVie will pay I-Mab USD 180 million in an upfront payment to exclusively license lemzoparlimab, along with USD 20 million in a milestone payment based on the phase 1 results, for a total of USD 200 million.

In addition, I-Mab will be eligible to receive up to USD 1.74 billion in success-based milestone payments for lemzoparlimab, of which USD 840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestones. Upon commercialization of lemzoparlimab, AbbVie will also pay tiered royalties from low-to-mid teen percentages on global net sales outside of greater China.

[conix]

ABBV Chart

[Taurus69]

$abbv $94.86 v -0.34 (-0.36%)
Volume: 5,276,641 @08/21/20 7

[Argaponis]

Good for ABBVIE delay for Gilead Sciences & (galapagos) rheumatoid arthritis (RA)


Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.

The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.

“We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

“This CRL issued by the FDA is very disappointing given the robust and comprehensive data package provided. Despite today’s news, we continue to believe filgotinib has the potential to provide an effective, new treatment option for patients with rheumatoid arthritis, where there remains a significant unmet need,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos.

The MANTA and MANTA-RAy studies are fully recruited, with topline results anticipated in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world. Filgotinib recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending marketing authorization for filgotinib in the EU for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.

[Taurus69]

$abbv $92.8 ^ 0.23 (0.25%)
Volume: 5,227,110 @08/07/20 7:59:47 PM EDT

[Taurus69]

$abbv $94.31 v -1.63 (-1.70%)
Volume: 7,865,116 @08/04/20 7:58:12 PM EDT

[DewDiligence]

ABBV 2Q20 CC transcript:

https://finance.yahoo.com/m/72e19094-2a74-319d-aa5f-082cb3eec319/abbvie-(abbv)-q2-2020.html

[DewDiligence]

ABBV 2Q20 results/full-year-2020 guidance:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2020-financial-results.htm

New 2020 non-GAAP EPS guidance = $10.35-10.45, including $0.70 accretion from AGN acquisition.

[DewDiligence]

Atogepant phase-3 succeeds in migraine prevention:

https://finance.yahoo.com/news/abbvie-announces-positive-phase-3-124500900.html

[Taurus69]

$abbv $100.83 ^ 0.91 (0.91%)
Volume: 6,896,147 @07/17/20 7:51:43 PM EDT

[Taurus69]

$abbv $99.01

[DewDiligence]

ABBV’s DARPin receives CRL in AMD due to still-high rate of intraocular inflammation:

https://www.prnewswire.com/news-releases/allergan-an-abbvie-company-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol-301084188.html

Allergan, an AbbVie Company, and Molecular Partners (MOLN.SW)…today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational DARPin therapy for patients with neovascular (wet) age-related macular degeneration (nAMD).

The letter from the FDA indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of neovascular (wet) age-related macular degeneration (AMD).

Inasmuch as Abicipar pegol was reformulated to reduce intraocular inflammation from 15% to 9% (#msg-147952065), this CRL probably spells the end of the program.

[DewDiligence]

FDA approves Voluma for chin enhancement:

https://finance.yahoo.com/news/fda-approves-juv-derm-voluma-121500053.html

[TFMG]

$ABBV On breakout watch above $100



P/E ratio 17.15
Company profile
AbbVie , Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

[Taurus69]

$abbv $92.46 ^ 0.2 (0.22%)

[osama]

This is the biggest theft in history for human pockets. Why do companies not rise dramatically when the market jumps 1700 points! But when the market goes down, all companies scramble with the Dow

[$Pistol Pete$]

Nice close

[Taurus69]

$abbv $93.85 ^ 0.81 (0.87%)

[DewDiligence]

ABBV forms collaboration to develop COVID-19 antibody for prophylaxis and treatment:

https://www.prnewswire.com/news-releases/abbvie-harbour-biomed-utrecht-university-and-erasmus-medical-center-announce-collaboration-to-develop-monoclonal-antibody-therapy-to-prevent-and-treat-covid-19-301071164.html

[Taurus69]

$abbv $92.67 ^ 2.64 (2.93%)

[Taurus69]

$abbv $93.02

[conix]

ABBV Chart

[osama]

can any one explain why ABBV not moving it should be over 100$